Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC boosted its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 9.9% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 750,208 shares of the company’s stock after buying an additional 67,813 shares during the quarter. Geode Capital Management LLC’s holdings in Enliven Therapeutics were worth $19,164,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ELVN. FMR LLC increased its stake in Enliven Therapeutics by 10.6% in the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after purchasing an additional 601,611 shares in the last quarter. First Turn Management LLC purchased a new position in shares of Enliven Therapeutics in the second quarter worth approximately $9,657,000. Janus Henderson Group PLC raised its holdings in shares of Enliven Therapeutics by 43.0% during the third quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock valued at $26,611,000 after acquiring an additional 313,019 shares during the period. Ally Bridge Group NY LLC purchased a new stake in shares of Enliven Therapeutics in the 3rd quarter valued at approximately $5,998,000. Finally, Marshall Wace LLP acquired a new position in Enliven Therapeutics in the 2nd quarter worth approximately $4,489,000. Institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

ELVN has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. BTIG Research initiated coverage on Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 price target on the stock. Finally, Robert W. Baird raised their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $38.25.

Enliven Therapeutics Stock Down 1.5 %

ELVN stock opened at $22.37 on Friday. The firm has a 50 day moving average of $25.58 and a two-hundred day moving average of $24.27. Enliven Therapeutics, Inc. has a 12 month low of $10.90 and a 12 month high of $30.03. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -11.77 and a beta of 1.02.

Insiders Place Their Bets

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 847 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $30.00, for a total transaction of $25,410.00. Following the completion of the sale, the insider now owns 1,015,188 shares of the company’s stock, valued at $30,455,640. This represents a 0.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Benjamin Hohl sold 5,250 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50. The disclosure for this sale can be found here. Insiders have sold 124,945 shares of company stock valued at $3,478,624 over the last three months. 29.20% of the stock is currently owned by insiders.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.